Table 3.
Crude odds ratios of developing sepsis for 60 clinical characteristics stratified by sepsis type
| Any sepsis | Community-acquired sepsis | Hospital-acquired sepsis | |
|---|---|---|---|
| Crude OR (95% CI) |
Crude OR (95% CI) |
Crude OR (95% CI) |
|
| Activity limitations | 2.29 (2.20–2.38) | 2.28 (2.19–2.38) | 2.32 (2.04–2.65) |
| Alcohol problems | 2.26 (2.15–2.38) | 2.20 (2.09–2.32) | 2.86 (2.46–3.33) |
| Anemia | 1.99 (1.96–2.02) | 1.98 (1.95–2.01) | 2.10 (2.01–2.21) |
| Anorexia or bulimia | 1.54 (1.37–1.72) | 1.54 (1.37–1.74) | 1.49 (1.05–2.12) |
| Anxiety | 1.28 (1.23–1.34) | 1.27 (1.22–1.34) | 1.38 (1.19–1.59) |
| Arthritis | 1.29 (1.27–1.31) | 1.29 (1.28–1.31) | 1.25 (1.20–1.31) |
| Asthma | 1.30 (1.28–1.33) | 1.30 (1.28–1.33) | 1.30 (1.22–1.39) |
| Atrial fibrillation | 1.82 (1.79–1.85) | 1.81 (1.78–1.84) | 1.97 (1.86–2.08) |
| Autoimmune disease | 1.64 (1.60–1.67) | 1.63 (1.60–1.67) | 1.66 (1.56–1.78) |
| Cancer | 1.82 (1.80–1.85) | 1.83 (1.80–1.86) | 1.76 (1.67–1.84) |
| Cerebrovascular disease | 1.61 (1.58–1.64) | 1.61 (1.58–1.64) | 1.61 (1.52–1.70) |
| Chronic kidney disease | 2.45 (2.36–2.53) | 2.41 (2.32–2.50) | 2.78 (2.49–3.11) |
| Chronic liver + viral hepatitis | 2.95 (2.79–3.12) | 2.89 (2.72–3.08) | 3.46 (2.91–4.12) |
| Chronic sinusitis | 1.02 (0.98–1.06) | 1.03 (0.99–1.07) | 0.92 (0.81–1.05) |
| Connective tissue disorder | 1.62 (1.58–1.65) | 1.61 (1.58–1.65) | 1.65 (1.54–1.77) |
| COPD | 1.85 (1.82–1.89) | 1.87 (1.83–1.90) | 1.75 (1.65–1.86) |
| Dementia | 1.19 (1.17–1.22) | 1.22 (1.20–1.25) | 0.91 (0.85–0.98) |
| Depression | 1.52 (1.47–1.57) | 1.52 (1.47–1.58) | 1.52 (1.37–1.70) |
| Diabetes | 1.89 (1.86–1.92) | 1.87 (1.85–1.90) | 2.04 (1.95–2.15) |
| Diverticular disease intestine | 1.19 (1.16–1.21) | 1.18 (1.16–1.20) | 1.24 (1.17–1.32) |
| Dizziness | 1.15 (1.13–1.17) | 1.15 (1.13–1.17) | 1.18 (1.12–1.25) |
| DVT | 1.55 (1.47–1.64) | 1.56 (1.47–1.65) | 1.51 (1.25–1.82) |
| Dyspnea | 1.92 (1.89–1.95) | 1.91 (1.88–1.95) | 1.98 (1.88–2.09) |
| Epilepsy | 1.79 (1.72–1.86) | 1.80 (1.73–1.87) | 1.73 (1.53–1.95) |
| Falls | 1.83 (1.81–1.86) | 1.82 (1.80–1.85) | 1.92 (1.83–2.02) |
| Foot problems | 1.68 (1.62–1.75) | 1.67 (1.60–1.74) | 1.84 (1.63–2.08) |
| Fragility fracture | 1.36 (1.33–1.38) | 1.35 (1.32–1.38) | 1.42 (1.34–1.51) |
| Hearing impairment | 1.10 (1.09–1.12) | 1.10 (1.08–1.12) | 1.14 (1.08–1.19) |
| Heart failure | 2.25 (2.21–2.29) | 2.22 (2.18–2.26) | 2.54 (2.39–2.69) |
| Heart valve disease | 1.50 (1.44–1.56) | 1.46 (1.40–1.53) | 1.84 (1.63–2.08) |
| Hemiplegia | 2.05 (1.94–2.16) | 2.05 (1.93–2.17) | 2.01 (1.69–2.39) |
| HIV | 0.34 (0.17–0.66) | 0.34 (0.17–0.70) | 0.29 (0.04–2.20) |
| Housebound | 2.65 (2.62–2.69) | 2.66 (2.62–2.70) | 2.60 (2.48–2.72) |
| Hyperlipidemia | 1.14 (1.12–1.16) | 1.13 (1.11–1.15) | 1.20 (1.14–1.27) |
| Hypertension | 1.33 (1.31–1.34) | 1.32 (1.30–1.34) | 1.39 (1.34–1.45) |
| Hypotension/syncope | 1.47 (1.45–1.50) | 1.46 (1.44–1.49) | 1.55 (1.46–1.65) |
| Immunodeficiency disorder | 2.48 (2.43–2.54) | 2.49 (2.43–2.55) | 2.40 (2.22–2.59) |
| Inflammatory bowel disease | 1.57 (1.49–1.64) | 1.53 (1.45–1.61) | 1.94 (1.66–2.25) |
| Irritable bowel syndrome | 0.91 (0.88–0.94) | 0.91 (0.88–0.94) | 0.94 (0.85–1.04) |
| Ischemic heart disease | 1.42 (1.40–1.44) | 1.41 (1.39–1.43) | 1.49 (1.42–1.57) |
| Learning disability | 2.96 (2.65–3.32) | 3.02 (2.68–3.40) | 2.43 (1.64–3.61) |
| Memory cognitive problems | 1.29 (1.27–1.32) | 1.31 (1.28–1.33) | 1.19 (1.11–1.27) |
| Mobility transfer problems | 2.08 (2.03–2.13) | 2.07 (2.02–2.12) | 2.18 (2.01–2.35) |
| Multiple sclerosis | 3.05 (2.79–3.32) | 3.12 (2.85–3.42) | 2.30 (1.68–3.15) |
| Osteoporosis | 1.31 (1.28–1.34) | 1.31 (1.28–1.34) | 1.34 (1.25–1.43) |
| Pancreatitis | 1.99 (1.89–2.09) | 1.98 (1.88–2.09) | 2.04 (1.71–2.43) |
| Parkinson disease | 1.68 (1.62–1.75) | 1.69 (1.62–1.76) | 1.60 (1.41–1.82) |
| Peptic ulcer disease | 1.38 (1.34–1.41) | 1.38 (1.35–1.42) | 1.35 (1.24–1.46) |
| Peripheral vascular disease | 1.95 (1.91–1.99) | 1.94 (1.89–1.98) | 2.07 (1.93–2.22) |
| Prostate disorders | 1.03 (1.01–1.05) | 1.03 (1.01–1.06) | 0.99 (0.92–1.06) |
| Psoriasis or eczema | 1.20 (1.18–1.22) | 1.19 (1.18–1.21) | 1.23 (1.17–1.29) |
| RA connective tissue disorder | 1.58 (1.54–1.61) | 1.58 (1.54–1.62) | 1.57 (1.46–1.69) |
| Schizophrenia bipolar | 1.71 (1.63–1.79) | 1.72 (1.64–1.81) | 1.64 (1.41–1.92) |
| Skin ulcer | 2.56 (2.51–2.62) | 2.55 (2.50–2.61) | 2.69 (2.52–2.87) |
| Sleep disturbance | 1.38 (1.35–1.41) | 1.38 (1.35–1.41) | 1.38 (1.29–1.47) |
| Social vulnerability | 1.32 (1.29–1.36) | 1.31 (1.27–1.35) | 1.43 (1.32–1.56) |
| Thyroid disease | 1.22 (1.20–1.24) | 1.21 (1.19–1.24) | 1.28 (1.20–1.36) |
| Urinary incontinence | 1.58 (1.54–1.61) | 1.60 (1.56–1.64) | 1.36 (1.26–1.47) |
| Visual impairment | 1.29 (1.27–1.31) | 1.28 (1.27–1.30) | 1.36 (1.30–1.42) |
| Weight loss anorexia | 1.81 (1.73–1.90) | 1.80 (1.71–1.89) | 1.91 (1.65–2.21) |